Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer

MLA

Takeshi Terashima, et al. “Successful Second Conversion Surgery after Trastuzumab Deruxtecan for Recurrent HER2-Positive Gastric Cancer.” Clinical Journal of Gastroenterology, vol. 16, Jan. 2023, pp. 330–35. EBSCOhost, https://doi.org/10.1007/s12328-023-01764-3.

APA

Takeshi Terashima, Tatsuya Yamashita, Hisashi Takabatake, Shinichi Nakanuma, Jun Kinoshita, Shintaro Yagi, Eishiro Mizukoshi, Kenichi Harada, Sachio Fushida, & Shuichi Kaneko. (2023). Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer. Clinical Journal of Gastroenterology, 16, 330–335. https://doi.org/10.1007/s12328-023-01764-3

Chicago

Takeshi Terashima, Tatsuya Yamashita, Hisashi Takabatake, Shinichi Nakanuma, Jun Kinoshita, Shintaro Yagi, Eishiro Mizukoshi, Kenichi Harada, Sachio Fushida, and Shuichi Kaneko. 2023. “Successful Second Conversion Surgery after Trastuzumab Deruxtecan for Recurrent HER2-Positive Gastric Cancer.” Clinical Journal of Gastroenterology 16 (January): 330–35. doi:10.1007/s12328-023-01764-3.